SECORIM©-ABO facilitates ABO-incompatible transplantations through reduction of blood group A or B antibodies. SECORIM©-ABO enables transplantations across blood group barriers by specific removal the organ recipient’s blood group antibodies.

The treatment is an extra-corporeal procedure, which for the patient is similar to dialysis. The specific removal of antibodies by SECORIM©-ABO eliminates several of the side effects of other treatment methods, offering a substantial advantage over these methods.

SECORIM©-ABO is a immunoadsorbation column designed to exclusively reduce the number of A or B antibodies. SECORIM©-ABO has its greatest potential in living-donor kidney transplantation with further use for transplantation of liver, heart, lung, bone marrow and stem cells.

Transplantations across the blood group barrier without pretreatment is not possible, the organ or cells are rapidly attacked by the recipients immunodefence system. However, there are since 2003 protocols published which includes the use of specific anti-gen immunoadsorption and a new immunosuppression regimen which makes ABO-incompatible transplantations successful  with results similar to ABO-incompatible transplantations. It is estimated that number of transplantations from living donors could be increased by 30 to 40 percent. As an example, in Germany  2011, 19% of living donor kidney transplantations were ABO-incompatible.

The SECORIM©-ABO column uses trisaccharides to remove ABO-antibodies from the patient, a well-known method today.